The week of 2025-12-15, 21 holders filed a new Schedule 13D and 48 a new Schedule 13G reporting 5% or more of a company, and 0 13D filings stated in Item 4 an intent to influence the company. Open a company for every holder and the purpose each 13D states, quoted.
New Schedule 13D
New Schedule 13G
| Filed | Company | Holder | Percent | Filing |
|---|---|---|---|---|
| 2025-12-16 | YD Bio Ltd | Ethan Shen | 77.1% | SCHEDULE 13G |
| 2025-12-15 | Daedalus Special Acquisition Corp. | Daedalus Special Acquisition LLC | 26.4% | SCHEDULE 13G |
| 2025-12-15 | Quoin Pharmaceuticals Ltd. | Ikarian Capital, LLC | 25.2% | SCHEDULE 13G |
| 2025-12-17 | Blueport Acquisition Ltd | Blueport Acquisition Corporation | 22.14% | SCHEDULE 13G |
| 2025-12-19 | Nuveen Churchill Direct Lending Corp. | Peakline Partners, LLC | 11.2% | SCHEDULE 13G |
| 2025-12-16 | DarioHealth Corp. | Craig Kallman 2015 Living Trust | 9.99% | SCHEDULE 13G |
| 2025-12-17 | C3is Inc. | L1 Capital Global Opportunities Master Fund, Ltd. | 9.99% | SCHEDULE 13G |
| 2025-12-17 | GRI Bio, Inc. | Mitchell P. Kopin | 9.99% | SCHEDULE 13G |
| 2025-12-18 | C3is Inc. | S.H.N. Financial Investments Ltd. | 9.99% | SCHEDULE 13G |
| 2025-12-19 | Blue Star Foods Corp. | Quick Capital, LLC | 9.99% | SCHEDULE 13G |
| 2025-12-15 | Intercont (Cayman) Ltd | Streeterville Capital LLC | 9.9% | SCHEDULE 13G |
| 2025-12-15 | Future FinTech Group Inc. | Avondale Capital, LLC | 9.9% | SCHEDULE 13G |
| 2025-12-16 | Quoin Pharmaceuticals Ltd. | Stonepine Capital Management, LLC | 9.9% | SCHEDULE 13G |
| 2025-12-16 | Algorhythm Holdings, Inc. | Streeterville Capital LLC | 9.9% | SCHEDULE 13G |
| 2025-12-17 | iBio, Inc. | EcoR1 Capital, LLC | 9.9% | SCHEDULE 13G |
| 2025-12-18 | Rezolute, Inc. | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2025-12-18 | Ovid Therapeutics Inc. | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G |
| 2025-12-18 | DNA X, Inc. | Streeterville Capital LLC | 9.9% | SCHEDULE 13G |
| 2025-12-15 | Hawthorn Bancshares, Inc. | Douglas Eden | 9.4% | SCHEDULE 13G |
| 2025-12-17 | Vista Credit Strategic Lending Corp. | Partners Capital LLP | 9.2% | SCHEDULE 13G |
| 2025-12-18 | Under Armour Inc | V. Prem Watsa | 9% | SCHEDULE 13G |
| 2025-12-18 | Ovid Therapeutics Inc. | Affinity Asset Advisors, LLC | 9% | SCHEDULE 13G |
| 2025-12-19 | iBio, Inc. | Logos Global Management LP | 8.9% | SCHEDULE 13G |
| 2025-12-16 | iBio, Inc. | Frazier Life Sciences Public Fund, L.P. | 8.7% | SCHEDULE 13G |
| 2025-12-15 | Silvia, Inc. | Steadfast Capital Management LP | 7.3% | SCHEDULE 13G |
| 2025-12-18 | Broadway Financial Corporation | M3 Funds, LLC | 7.16% | SCHEDULE 13G |
| 2025-12-15 | Forum Markets Inc | Zippy, Inc. | 7.1% | SCHEDULE 13G |
| 2025-12-18 | Fusion Fuel Green PLC | Bower Four Capital Corp | 6.52% | SCHEDULE 13G |
| 2025-12-16 | Karbon Capital Partners Corp. | Millennium Management LLC | 6.4% | SCHEDULE 13G |
| 2025-12-18 | Amc Entertainment Holdings, Inc. | Discovery Capital Management, LLC | 6% | SCHEDULE 13G |
| 2025-12-18 | Ur-Energy Inc | enCore Energy Corp. | 6% | SCHEDULE 13G |
| 2025-12-15 | Atlas Lithium Corporation | Kenneth Griffin | 5.9% | SCHEDULE 13G |
| 2025-12-19 | Iron Horse Acquisition II Corp. | MMCAP International Inc. SPC | 5.9% | SCHEDULE 13G |
| 2025-12-18 | Trulieve Cannabis Corp. | Marex Securities Products Inc. | 5.8% | SCHEDULE 13G |
| 2025-12-19 | Churchill Capital Corp XI | MMCAP International Inc. SPC | 5.8% | SCHEDULE 13G |
| 2025-12-19 | Vor Biopharma Inc. | Frazier Life Sciences Public Fund, L.P. | 5.8% | SCHEDULE 13G |
| 2025-12-17 | Vor Biopharma Inc. | Great Point Partners, LLC | 5.63% | SCHEDULE 13G |
| 2025-12-15 | Hinge Health, Inc. | Jane Street Group, LLC | 5.6% | SCHEDULE 13G |
| 2025-12-17 | Ur-Energy Inc | MMCAP International Inc. SPC | 5.4% | SCHEDULE 13G |
| 2025-12-19 | ITHAX Acquisition Corp III | Tenor Capital Management Company, L.P. | 5.4% | SCHEDULE 13G |
| 2025-12-19 | Burning Rock Biotech Ltd | Crcm LP | 5.38% | SCHEDULE 13G |
| 2025-12-16 | Daedalus Special Acquisition Corp. | Linden Advisors LP | 5.3% | SCHEDULE 13G |
| 2025-12-17 | Actuate Therapeutics, Inc. | Voss Capital, LP | 5.3% | SCHEDULE 13G |
| 2025-12-19 | Rezolute, Inc. | Opaleye Management Inc. | 5.3% | SCHEDULE 13G |
| 2025-12-19 | Twelve Seas Investment Co III | Tenor Capital Management Company, L.P. | 5.2% | SCHEDULE 13G |
| 2025-12-15 | Neurogene Inc. | Trails Edge Capital Partners, LP | 5.1% | SCHEDULE 13G |
| 2025-12-19 | Twelve Seas Investment Co III | Linden Advisors LP | 5.1% | SCHEDULE 13G |
| 2025-12-17 | Cable One, Inc. | D. E. Shaw & Co., L.P. | 5% | SCHEDULE 13G |
Stated intent
No 13D this week stated an intent to influence the company.
Tools for this story
Each opens in a new tab. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.